IDH1 and glioblastoma: We assessed the model predictions from setup 1 for differentiating favorable from unfavorable prognosis in the important subgroups of IDH1 wild-type glioblastoma patients ≤70 and >70 years of age to evaluate the model predictions for treatment selection.